Evaluation of intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients.

CONCLUSIONS: Dalbavancin 1500 mg intravenously can be utilized without dose adjustment in peritoneal dialysis patients and will likely achieve necessary peritoneal fluid concentrations to treat peritonitis caused by typical gram-positive pathogens. PMID: 32122898 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32122898?dopt=Abstract

Source: Antimicrobial Agents and Chemotherapy - March 1, 2020 Category: Microbiology Authors: Van Matre ET, Teitelbaum I, Kiser TH Tags: Antimicrob Agents Chemother Source Type: research